Search Results for "Sjogren A Belimumab"

08:07 EST 28th November 2015 | BioPortfolio

Matching Channels


Matching News

GSK Announces Positive Results From Phase III BLISS-SC Study of Benlysta® (Belimumab) Administered Subcutaneously In Patients With Systemic Lupus Erythematosus (SLE)

SAN FRANCISCO and LONDON, Nov. 10, 2015 /PRNewswire/ -- On Saturday, Nov. 7, GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lup...

Arthritis Is Major Risk With Antibody-Positive Sjogren?s

(MedPage Today) -- And almost a third of patients developing RA had the erosive form

GSK announces Phase III results for belimumab in SLE

Families with SLE Face Risk for Sjogren’s Syndrome (CME/CE)

(MedPage Today) -- Two autoimmune diseases share clinical and serological features

Subcutaneous Benlysta belimumab: Phase III data

Understanding, Diagnosing, and Treating Sjogren Syndrome

Dr Fox reports on the 13th International Symposium on Sjogren's Syndrome and shares his perspective on advances in the field. Medscape Rheumatology

Systemic Complications Are Common in Sjögren Syndrome

A retrospective review of patients with Sjogren syndrome underlines the need for ophthalmologists to screen for this disorder as soon as its tell-tale signs present. Medscape Ophthalmology

GlaxoSmithKline drug achieves goals in lupus trial

GlaxoSmithKline's Benlysta, or belimumab, combined with standard of care, met the primary and secondary endpoints of a late-s -More- 

Matching PubMed Articles

A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.

Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients af...

Belimumab in systemic lupus erythematosus: a perspective review.

Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by...

Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain.

To estimate the cost-effectiveness of belimumab in patients with systemic lupus erythematosus (SLE) presenting positive biomarkers and active disease despite standard treatment (ST), from the Spanish ...

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

The purpose of this analysis is to evaluate the cost-effectiveness of belimumab, a new biological treatment specifically developed for the treatment of Systemic Lupus Erythematosus (SLE), in the Itali...

Rare association: Sjogren Syndrome and liposarcoma of the parotid.

Search Whole site using Google


Advertisement Advertisement